Vera Therapeutics (VERA) Reiterated at Overweight by Cantor Fitzgerald on Trutakna Approval

July 8, 2026 7:47 AM

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating and $100.00 price target on Vera Therapeutics (NASDAQ: VERA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found